The uptake of the once-every-six-month HIV prevention jab lenacapavir (LEN) in South Africa will be heavily affected by the Trump administration's funding cuts to the country, a new report has found.
By Lulah Dube JOHANNESBURG, April 21 (Reuters) - U.S. funding cuts to South Africa have dismantled HIV prevention programmes ...
The uptake of the once-every-six-month HIV prevention jab lenacapavir (LEN) in South Africa will be heavily affected by the ...
Add Yahoo as a preferred source to see more of our stories on Google. A laboratory technician Nozipho Mlotshwa works on samples at the Wits laboratory Antiviral Gene Therapy Research Unit, at ...
JOHANNESBURG — South Africa's health minister on Tuesday called lenacapavir, the first twice-yearly HIV prevention jab in the world, a “groundbreaking” tool to fight the disease, but warned initial ...
JOHANNESBURG (AP) — Just a week had remained before scientists in South Africa were to begin clinical trials of an HIV vaccine, and hopes were high for another step toward limiting one of history’s ...
JOHANNESBURG — Just a week had remained before scientists in South Africa were to begin clinical trials of an HIV vaccine, and hopes were high for another step toward limiting one of history’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results